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Abstract
Background Benzodiazepines (BZD) and benzodiazepine
receptor agonists (zolpidem, zaleplon, zopiclone, altogether
Z-drugs) are most commonly prescribed for the treatment of
insomnia. However, long-term use of BZD/Z-drugs is asso-
ciated with major adverse events including, but not limited
to, falls and fractures, domestic and traffic accidents, con-
fusion, cognitive impairment, Alzheimer's disease and can-
cer. The prolonged use of these drugs is thought to be related
to severe withdrawal symptoms and potential dependency.
The chronic and extensive use of BZD/Z drugs has become
a public health issue and has led to multiple campaigns to
reduce both prescription and consumption of BZD/Z-drugs.
Prolonged-release (PR) melatonin is the first of a new class
of melatonin receptor agonist drugs that has demonstrated
clinically relevant efficacy on improving quality of sleep
and morning alertness, with a good safety profile.
Objective This study aimed to analyze and evaluate the
impact of anti-BZD/Z-drugs campaigns and the availability
of alternative pharmacotherapy (PR-melatonin) on the
consumption of BZD and Z-drugs in several European
countries.
Methods Annual sales data from nine European countries
were extracted from the IMS sales database and analyzed to
determine whether trends in use of these treatment options
were attributed to campaigns and/or availability and afford-
ability of safer alternatives on the market.
Results Campaigns aiming to reduce the use of BZD/Z-drugs
failed when they were not associated with the availability and
market uptake of PR-melatonin. The reimbursement of PR-
melatonin supports better penetration rates and a higher
reduction in sales for BZD/Z-drugs.
Keywords Insomnia . Benzodiazepines (BZD) .
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Introduction
Insomnia is a disorder characterized by difficulties in initiating
and/or maintaining sleep, nighttime or early awakenings, and
nonrestorative or poor quality sleep for at least 1 month [1, 2].
Its diagnosis is further subdivided into primary insomnia with
an absence of comorbid conditions, and secondary insomnia if
it is associated with other conditions (physical, mental, envi-
ronmental causes). Insomnia is associated with clinically sig-
nificant daytime distress resulting in a reduced quality of life.
Mental health problems, such as a reduction of cognitive
abilities, memory and attention, as well as cardiovascular,
respiratory and metabolic disorders are associated with insom-
nia [3]. Direct and indirect costs of insomnia represent a
substantial societal economic burden [4]. The prevalence of
primary insomnia ranges from 1 % to 10 % in the general
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population and up to 25–30 % in the elderly, [5–9] for whom
treatment of insomnia is a clear medical need.
Benzodiazepines (BZD) and benzodiazepine receptor
agonists (zolpidem, zaleplon, zopiclone, altogether Z-
drugs) are most commonly prescribed for the treatment of
insomnia [10, 11]. A meta-analysis of the risks and benefits
of these therapeutic options in elderly patients reported
statistically significant improvements in sleep, but also
reported a statistically significant risk of adverse events
[12, 13], including life-threatening ones [14]. Indeed these
drugs are only approved by regulatory authorities for 2–
4 weeks because of safety concerns. The Z-drugs, which
unlike BZD are used exclusively for the treatment of insom-
nia, were thought to have a lesser tendency to induce phys-
ical dependence and addiction than BZDs [15], and are
therefore widely prescribed for the treatment of insomnia,
particularly in elderly patients [16–18]. Nevertheless, safety
issues are still a matter of concern [19–25]. Long-term BZD
and Z-drug use is not recommended, as tolerance and ad-
diction can occur [26]. A population-based survey of
patients using Z-drugs and BZD hypnotics found that Z-
drug users were more likely to report that they had tried to
stop using their hypnotic drug and were more likely to want
to stop taking Z-drugs than BZD users. Adverse effects were
reported in over 41 % of users with no difference between
these two classes. Efficacy also did not differ between Z-
drugs and BZD users [13].
In patients over 60 years of age, chronic BZD or Z-drug
use carries the risk of exacerbations of pre-existing psycho-
motor or cognitive impairment, which may result in an
increased risk of falls, motor vehicle collisions, household
accidents or confusion and memory problems [27]. Recent
studies have also pinpointed the potential increased risk of
Alzheimer’s disease [28], cancer, and mortality [29] after
chronic consumption of hypnotic drugs.
These safety concerns relating to the treatment of insom-
nia with hypnotic drugs, as well as the possibility of depen-
dence, are a significant public health issue.
It has also been demonstrated that in some countries such
as France, BZD and Z-drugs are overused and prescribed for
a much longer time than the indicated 4 weeks [26, 30]. As a
result, more and more health authorities in Europe are initi-
ating policies and recommendations in order to decrease the
consumption of BZD and Z-drugs [30–35]. However, the
anti-BZD and Z-drug campaigns initiated in most countries
have been unsuccessful, and despite the guidelines and
national recommendations, the use of BZD and especially
Z-drugs has continued to increase.
Prolonged-release (PR) melatonin is the first of a new
class of drugs known as “melatonin receptors agonists,” and
is a non-sedative hypnotic which has demonstrated clinical-
ly relevant efficacy on quality of sleep and morning alert-
ness, with a good safety profile [36–39]. No evidence of
dependence, withdrawal effects, rebound insomnia or nega-
tive influence on daytime alertness has been observed with
its use [40, 41]. Several clinical trials demonstrated that PR-
melatonin could help reduce BZD and Z-drugs consumption
[42, 43].
PR-melatonin is only available as trade name Circadin,
manufactured by Neurim Pharmaceuticals, Tel-Aviv, Israel.
PR-melatonin 2 mg is the only alternative to BZD and Z-
drugs, approved by the European Medicines Agency (EMA)
in 2007 for patients aged 55 or over, as monotherapy for the
short-term treatment (up to 13 weeks) of primary insomnia.
As PR-melatonin was launched in many European mar-
kets in 2008, it was interesting to evaluate how campaigns to
decrease BZD and Z-drugs prescriptions affected consump-
tion of these drugs in real life, with or without market uptake
of PR-melatonin.
Objectives
The objective of this study was to analyze and evaluate the
impact of anti-BZD/Z-drug use campaigns and the availabil-
ity of alternative pharmacotherapy (PR-melatonin) on the
consumption of BZD and Z-drugs in several European
countries.
Methodology
The selection of European countries considered in the scope
of this study was based on two criteria: countries having
national or regional (in Spain) anti-BZD campaigns, and/or
countries where PR-melatonin was launched and reached at
least 4 % volume market share of the total insomnia market
for N5B1 (NON-BARBITURATE PLAIN). The countries
with anti-BZD campaigns were selected after reviewing
their respective Ministry of Health, national public health,
HTA agency, and regional health authorities’ websites. To
determine countries with significant PR-melatonin market
share, the IMS sales database was used. IMS Health is a
global company that provides information, services and
technology for the healthcare industry. The market volume
is defined as the ratio of the number of PR-melatonin
standard units sold to the total number of standard units
sold for the treatment of insomnia. The Standard Unit
(SU) is the smallest drug dose available on the market.
The level of 4 % was considered to be a significant pene-
tration rate—when the other hypnotics are generics with a
price that is around 8 times lower, and the indication for PR-
melatonin is only for insomnia patients aged over 55 while
for the competitors are for all ages, 4 % in volume can
reasonably be considered a significant penetration rate. It
corresponds to approximately 20 % in value.
Eur J Clin Pharmacol
The European countries in the scope of this study were:
Finland, Norway, Denmark, Sweden, Greece, France, the
Netherlands, Spain and the United Kingdom.
This study was completed using the annual sale volumes
of BZD/Z-drugs and PR-melatonin for each country in the
scope, extracted from the IMS sales database. Data is
expressed in SU. For each country, we studied the evolution
of BZD/Z-drug sales volumes (together and separately)
3 years prior to the launch of PR-melatonin (at the end of
2007) and then 4 years after the launch of PR-melatonin
(2011), as well as the evolution of PR-melatonin sales
volumes. Additional parameters considered in the interpre-
tation of the data were: the launch strategy of PR-melatonin
(actively promoted/not promoted), product positioning and
key messages, national or regional anti-BZD/Z-drugs cam-
paigns (the type of campaign, their target and the recom-
mendations), the penetration rate of PR-melatonin in 2011
and its reimbursement status compared to BZD/Z-drugs. As
only the volume of sales is available in these databases, the
assumption was made that the volume sold was equal to the
prescribed and consumed volumes.
Results
Table 1 presents market status of BZD/Z hypnotics and PR-
melatonin for the countries within the scope of the study.
The market trends for each country are depicted in Figs. 1,
2, 3, 4, 5, 6, 7, 8, 9 and are detailed below, by country.
Finland
In Finland, health authorities have been carrying out an anti-
BZD campaign since 2005 [33]. This government-driven
campaign was supported by publications and guidelines
with negative recommendations on BZD and Z-drug use.
PR-melatonin was launched in January 2008 and marketed
actively, but was not reimbursed, while BZDs and Z-drugs
are partially reimbursed. The price of PR-melatonin in Fin-
land is about eight times higher (0.55€ ex-factory/day) than
the mean price of BZD/Z-drugs (0.07€ ex-factory/day).
Nevertheless, patients are used to paying for medications
and the impact of price on patient decisions is limited.
As depicted in Fig. 1, BZD/Z-drug consumption
remained stable between 2005 and 2007. More precisely,
BZD sales decreased in proportion to the increase in Z-drug
sales. Since the launch of PR-melatonin in 2008, BZD and
Z-drugs sales have decreased substantially, with a reduction
of up to 20.2 % between 2008 and 2011. PR-melatonin sales
increased gradually between 2008 and 2011, to reach 5.1 %
in volume (SU) market share and 27.1 % in value market
share in 2011. In 2011, 5 million SUs of PR-melatonin were
sold whereas the annual sales of BZD/Z-drugs reduced by
16.6 million SUs compared to 2005.
Norway
In Norway, an important anti-BZD government driven cam-
paign was initiated in 2005 [44]. This campaign was sup-
ported by guidelines and especially focused on the issue of
driving and BZD/Z-drug consumption [44]. PR-melatonin
was launched in Norway in January 2008, but was not
reimbursed. BZD and Z-drugs were not reimbursed as well.
Despite the anti-BZD campaign prior to the launch of
PR-melatonin, BZD/Z-drug net consumption increased by
7.3 % between 2005 and 2007. BZD volume sales decreased
(9.3 %) whereas Z-drug sales increased (11.7 %) during this
period. After its launch in January 2008, PR-melatonin
reached a volume market share of 4.5 % and a value market
share of 21 % in 2011. BZD consumption decreased by
13.4 % between 2008 and 2011, whereas Z-drugs sales
stabilized (+1.0 %).
Denmark
The Danish Institute of Rational Pharmacotherapy (within the
Danish Medicines Agency) started a campaign against the use
of BZD and Z-drugs in 2008, with three brochures provided to
physicians, citizens and pharmacies [45]. They pinpoint the fact
that long-term consumption of BZD and Z-drugs is associated
with health risks. Approximately 100,000 people in Denmark
permanently consume BZDs and are addicted to them [45].
PR-melatonin was launched in October 2007, without
reimbursement status, similar to BZD/Z-drugs that are also
not reimbursed. PR-melatonin was not recommended as
first-line therapy in the treatment of primary insomnia
[46]. Since Denmark citizens are used to paying for insom-
nia drugs, the non-reimbursement status did not differentiate
PR-melatonin from BZD/Z-drugs.
Between 2005 and 2007, Z-drug sales remained at the
same level whereas BZD sales started to decrease slightly,
despite the absence of an anti-BZD campaign. In 2008, a
campaign was launched alongside the introduction of PR-
melatonin. PR-melatonin’s market share reached 3.7 % of
volume in 2011 and 21 % in value market share in 2011.
From 2008, the sale of BZD/Z-drugs decreased quite sub-
stantially (by 24.7 %).
Sweden
In Sweden, all BZD and Z-drugs are reimbursed. An anti-
BZD campaign was launched in 2001 [47], resulting in a
stagnation of the sales of BZD, with an increase of Z-drugs
sales. PR-melatonin was launched but was the only non-
reimbursed hypnotic. It represented only 1 % of volume
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market share and 11 % of value market share in 2011, as
shown in Fig. 4. The BZD consumption rate was quite stable
(−3.2 %) whereas sales of Z-drugs rose steadily (+20.5 %)
from 2005 to 2011.
France
In France, health authorities are concerned about the over-
use of BZD and Z-drugs. An initial report warning about the
use of BZD/Z-drugs was issued in the early 90s [48], fol-
lowed by a series of reports issued upthrough 2010 and
many campaigns, the most prominent being in 2008 [26].
The risks of these products are well known, and the Haute
Autorité de Santé (HAS) is trying to reduce their consump-
tion. The HAS has published detailed recommendations on
how to help patients withdraw from the use of BZD: “Psy-
cho SA - Plaintes du sommeil-Insomnie 2010” [26]. Also,
the Agence Française de Sécurité Sanitaire Produits de
Santé (AFSSaPS) addressed the high levels of BZD con-
sumption in France through a review of the last 10 years
[30], and tried to reduce consumption by controlling use and
strengthening the measures already initiated to promote the
appropriate consumption of BZD and Z-drugs.
PR-melatonin was introduced to the French market in
June 2008. The product was not actively promoted in
France, since it was not reimbursed while all other hypnotics
were reimbursed. The price was eight times higher than the
mean BZD price. As French patients are not used to paying
for their medication “out of pocket,” there was a substantial
disincentive for choosing PR-melatonin prescriptions.
As observed in Fig. 5, the sales of BZD/Z-drugs did not
change significantly following the recommendations of the
HAS, with the global variation of +1.8 %. More precisely,
BZD sales decreased by −6.0 % whereas Z-drug sales in-
creased by +4.7 % during the campaign. From 2007, both
BZD and Z-drug sales remained stable despite the various
reports and campaigns issued by the health authorities. PR-
melatonin sales were negligible.
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Fig. 1 Finland. Despite the anti-BZD campaign, BZD/Z-drugs con-
sumption remained stable until the introduction of PR-melatonin. At
PR-melatonin’s launch in 2008, BZD and Z-drugs sales decreased
substantially between 2008 and 2011
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Fig. 2 Norway. Despite the anti-BZD campaign prior to the launch of
PR-melatonin, BZD/Z-drug net consumption increased between 2005
and 2007. BZD volume sales decreased whereas Z-drug sales in-
creased. After PR-melatonin launch, BZD consumption decreased by
13.4 % between 2008 and 2011, whereas Z-drugs sales have stabilized.
PR-melatonin reached a volume market share of 4.5 % in 2011
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Fig. 3 Denmark. Despite the absence of an anti-BZD campaign be-
tween 2005 and 2007, BZD sales started to decrease slightly whereas
Z-drug sales remained at the same level. From 2008, when both PR-
melatonin and a BZD campaign was launched, the BZD/Z-drugs sales
decreased quite substantially
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Fig. 4 Sweden. The BZD consumption rate is quite stable whereas Z-
drugs sales rose steadily from 2005 to 2011 despite the anti-BZD
campaign. PR-melatonin sales were negligible
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Greece
No anti-BZD campaign has been initiated in Greece. PR-
melatonin was launched in January 2008 and reimbursed
like all other hypnotics.
Before PR-melatonin’s launch, consumption of BZD/Z-
drugs decreased by 5.9 % between 2005 and 2007 (Fig. 6).
After the launch, this phenomenon accelerated, with a decrease
of 14.5 % in BZD/Z-drug consumption between 2008 and
2011. PR-melatonin penetration was progressive, reaching
5.5 % of volume market share and 28 % of value market share
in 2011. Compared to sales in 2005, the annual sales of BZD/Z-
drugs decreased by more than 11 million SUs. Approximately
2.4 million SUs of PR-melatonin were sold during 2011.
The Netherlands
The Netherlands College of General Practitioners recommen-
ded that BZD and Z-drugs should be prescribed only for short
courses, and should generally be avoided in elderly patients.
Indeed, around 30 % of Dutch patients using these compounds
are chronic users [49]. In January 2009, the reimbursement
status of BZD and Z-drugs changed, and became excluded
from the Dutch reimbursement schemes. The aim of this
change was to reduce the use of these medications for chronic
use, and to limit the health care expenditures (high level of costs
due to the volume of BZD use). After ending reimbursement,
the Dutch Foundation for Pharmaceutical Statistics reported a
16 % reduction in the overall use of BZDs and Z-drugs [50].
In the Netherlands, PR-melatonin was launched without a
reimbursement status. As shown in Fig. 7, the sales of PR-
melatonin were negligible. Looking separately at BZDs and
Z-drugs (Fig. 7), BZD sales decreased by −19.4% whereas Z-
drug sales were stable (−3.6 %) between 2008 and 2011 and
since the ending of reimbursement in 2009, both BZD and Z-
drugs sales are stable.
United Kingdom
In the United Kingdom, recommendations to restrict BZD
and Z-drug usage were published on 2004, by the Depart-
ment of Health (DoH) [51]. In this recommendation, doctors
are warned that benzodiazepines should only be prescribed
for short-term treatment, in light of evidence of problems
associated with long-term use.
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Fig. 5 France. BZD sales decreased whereas Z-drug sales increased
during the anti-BZD campaign. From 2007, both BZD and Z-drug
sales remained stable despite the various reports and campaigns. PR-
melatonin sales were negligible
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Fig. 6 Greece. Between 2005 and 2007, there was a decrease of BZD/
Z-drug consumption. After the PR-melatonin launch in 2008, this
phenomenon accelerated, with a bigger decrease of the BZD/Z con-
sumption between 2008 and 2011. The PR-melatonin’s penetration was
progressive, finally reaching 5.5 % of volume market share
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Fig. 7 The Netherlands. The sales of PR-melatonin were negligible.
Looking separately at BZDs and Z-drugs, BZD sales decreased sharply
whereas Z-drug sales were stable between 2008 and 2011
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Fig. 8 The UK. The decrease in BZD SUs between 2005 and 2010
was steady. Similarly, the sales of Z-drugs increased during this period.
PR-melatonin sales were negligible in the UK
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PR-melatonin was launched in 2008 and automatically
reimbursed in the UK, but was not recommended by the
National Institute of Clinical Excellence (NICE) and the
Scottish Medicines Consortium (SMC).
The decrease in BZD SUs between 2005 and 2010 was
steady, up to 31.7 % less, as shown in Fig. 8. Concurrently,
the sales of Z-drugs increased during this period (+7.4 %).
PR-melatonin sales were negligible in UK.
Spain
Campaigns were conducted at regional levels; in addition,
PR-melatonin was approved, but not reimbursed and thus
was not put on the market.
As shown in Fig. 9, there was a substantial 20 % increase
in BZD and Z-drug consumption between 2005 and 2011.
Discussion
The results of this analysis suggest there are three common
groups among the studied countries, with different BZD/Z-
drug consumption trends:
– Countries where the sales of BZD and Z-drugs de-
creased since 2007: Greece, Finland and Denmark.
In Greece there was no anti-BZD campaign before
the launch of PR-melatonin, and the consumption of the
BZD and Z-drugs was stable. BZD and Z-drug con-
sumption decreased by 14.5 % over 3 years after the
introduction of PR-melatonin in the market. The de-
crease in BZD/Z drug consumption since 2008 can thus
be attributed to the launch of PR-melatonin and its
considerable market penetration. On average, an in-
crease in 1 SU of PR-melatonin was associated with a
decrease of about 4 SUs of BZD/Z-drugs.
The combined launch of PR-melatonin and anti-BZD
campaigns in Finland and Denmark seems to be
associated with a reduction of BZD/Z-drugs usage. This
decrease is concomitant with the penetration of PR-
melatonin on the market and the campaign implemen-
tation. Again, uptake of 1 SU PR-melatonin in Finland
was associated with a decrease of 3 SUs of BZD/Z
drugs consumption in this country.
– Countries where the sales of BZD decrease while Z-
drugs increase: Norway, the Netherlands and the UK. In
these countries the anti-BZD campaigns seem effective
for BZDs, but essentially resulted in a shift in prescrip-
tion patterns towards Z-drugs.
In Norway, there was an overall increase in BZD/Z drugs
consumption since 2005 but the BZD sales decreased in
favor of Z-drugs. Since PR-melatonin was launched, the
increase in Z-drug sales stopped and the consumption was
stabilized, as if the switch from BZDs gradually shifted from
Z-drugs to PR-melatonin.
The same evolution of BZD and Z-drug sales was ob-
served in the Netherlands, but the decrease in BZD sales
was mostly related to the change in the reimbursement
status, suggesting that BZD/Z drug consumption in this
country is price sensitive and reimbursement itself has some
encouraging effect on hypnotic drug consumption. Never-
theless, Z-drug sales remained stable between 2009 and
2011. PR-melatonin sales did not rise considerably in the
Netherlands perhaps because it is more expensive than the
other drugs and is not actively promoted in this country.
In the UK, a decrease was seen only in BZD. There was a
steady increase in Z-drug use of up to 7.3 % in 2011, although
NICE has issued the following recommendation: "It is recom-
mended that, because of the lack of compelling evidence to
distinguish between zaleplon, zolpidem, zopiclone or the
shorter-acting benzodiazepine hypnotics, the drug with the
lowest purchase cost (taking into account daily required dose
and product price per dose) should be prescribed” [52]. Pos-
sibly, higher market acceptance of PR-melatonin might grad-
ually change this situation as seen in Norway.
– Countries where the sales of BZD were stable and Z-
drug use increased, resulting in overall increases in
BZD and Z-drug sales despite anti-BZD campaigns:
France, Sweden and Spain.
– In these countries the anti-BZD/Z-drug campaigns that
were sometimes quite intense and long lasting (like in
France) had no or very limited impact on prescription
levels. As BZDs and Z-drugs are reimbursed while PR-
melatonin is not, and these markets are reimbursement-
sensitive, PR-melatonin was not commercially launched
in France and was not put on the market in Spain.
Although real-life outcomes are difficult to interpret, as
many factors could contribute to the occurrence of the
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Fig. 9 Spain. There was a substantial increase in BZD and Z-drug
consumption between 2005 and 2011 and PR-melatonin was not on the
market
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outcome, some conclusions may be drawn with a reasonable
level of certainty in the light of this research.
In countries where BZD/Z-drug campaigns were
launched and PR-melatonin was not promoted nor pre-
scribed, all campaigns failed to reach the desired outcome.
This was the case for France, Spain, and Sweden.
In Greece, where no campaign was initiated, the sales re-
duction of BZD/Z-drugs was concomitant with PR-melatonin
uptake. The case of Greece is a robust argument in favor of the
role of PR-melatonin in the reduction of BZD/Z-drug sales.
In Finland and Denmark, the concomitant launch of
BZD/Z-drug campaigns and PR-melatonin made it difficult
to weight the impact of each factor on the reduction of BZD/
Z-drug sales. However, in Finland the 3-year campaign from
2005 to 2008 ended with no appreciable effect at the launch
of PR-melatonin. The drop of BZD/Z-drug sales clearly
followed the uptake of PR-melatonin.
It should be noted that a standard unit is the smallest
available drug dose. For PR-melatonin, an SU is the defined
daily dose (DDD), as there is only one dosage available on
the market. For BZD/Z-drugs there are often several dos-
ages and therefore more than one SU may account for a
DDD. Thus, the volume of BZD/Z-drugs in SUs replaced by
the sales of PR-melatonin is higher than the raw number of
SUs of PR-melatonin sold. In addition, the lower SU vol-
umes of sold PR-melatonin as compared to unsold BZD/Z-
drug SU volumes may in part reflect the fact that PR-
melatonin can be discontinued without difficulty while
BZD/Z-drugs cause withdrawal, tolerance and dependency,
making discontinuation very difficult and causing abuse.
In Norway, the prescription shift of BZD toward Z-drugs
stopped suddenly when PR-melatonin was launched. PR-
melatonin appears to be a successful alternative option to Z-
drugs.
In the UK and the Netherlands, in the absence of PR-
melatonin uptake the reduction of BZD sales was associated
with an increase of Z-drug use. The objective of total reduc-
tion was not achieved. The shift cannot be considered a
success of the anti BZD/Z drug campaign, as the risk asso-
ciated with Z-drugs is not considered significantly different
from BZD in most studies [27]. Some studies found Z-drugs
to be even worse [53].
The marketing strategy toward positioning and promotion of
pharmaceutical products is a critical element of the medical
practice [54]. In this case in Greece, Finland, Denmark and later
Norway, unlike Sweden, PR-melatonin was perceived as an
option to help chronic users withdraw from BZD/Z-drugs.
Although this was not the only positioning, it was an important
element of themarketing strategy also leading to volumemarket
shares of 4–5.5 %. In those countries, the sales of PR-melatonin
were associated with a decrease of BZD/Z-drug sales.
The lack of success of anti-BZD/Z-drug campaigns in the
absence of an alternative pharmacological treatment option
(France, Sweden) raises the question of the utility of such
campaigns. Even if BZD drugs were actually reduced in
countries like the UK and Norway, they were always associ-
ated with a shift in prescription toward another pharmacolog-
ical agent, namely Z-drugs alone (UK) or Z-drugs followed by
PR-melatonin when it became available (Norway).When both
PR-melatonin and Z-drugs were available the prescriptions
were consistently channeled toward PR-melatonin, resulting
in a net decrease of the whole sedative hypnotics class includ-
ing BZDs and Z-drugs (Finland and Denmark). The availabil-
ity on the market of pharmacological alternative options to
replace BZD/Z-drugs appears to be a critical factor for success
of such campaigns. In the Netherlands, despite the fact that
reimbursement was ended for both BZD and Z-drugs, there
was a shift toward Z-drug prescription for some of the
patients. It is unclear how the other patients were managed.
Additionally, no information is available on alternative phar-
macological or nonpharmacological prescriptions. Therefore,
it is not possible to appreciate potential harm associated with
this shift in practice.
The adoption of PR-melatonin as a treatment option is
also important for BZD/Z drug use in countries where the
product is reimbursed (e.g. the UK and Greece). In the UK
the PR-melatonin launch was not associated with an HTA
recommendation and sales didn’t take off, as the recommen-
dation is a strong driver of general physician (GP) prescrip-
tions. However in Greece, where the adoption of PR-
melatonin was high, so was the decrease of sales of BZD/
Z-drugs despite the lack of campaigns.
In Spain, where PR-melatonin was not available and the
campaign was mild and geographically limited to regions,
and in France were the campaign was intense and national,
the sales of BZD/Z-drugs still tended to increase.
The findings of this study are consistent with a small size,
double-blind randomized clinical trial that has shown the
role of PR-melatonin in helping patients to withdraw from
BZD/Z-drug use [43]. It is also supported by an observa-
tional study showing a low rate of reinitiation of BZD/Z-
drug after a course of PR-melatonin when patients were
previously treated by BZD/Z-drugs [42].
The study has also some limitations.
No country without any campaigns and without a signif-
icant PR-melatonin existence was selected as control coun-
try. However, it is established that prescription habits of
doctors are deeply anchored and without any intervention,
no change occurs [55]. Moreover, in order to compare trends
with and without campaigns, some countries can be their
own control by comparing the period before with the period
after the launch of the campaign, for example France.
We used a database that is solely based on sales data and
not prescriptions. We assumed that sales figures are a good
proxy of what is consumed even if it is clearly higher.
Indeed, some sold drugs are not then consumed by the
Eur J Clin Pharmacol
patients. However, we assumed that the proportion of drugs
sold and actually consumed by patients is the same, what-
ever the product. There are no reasons to believe that the
proportion is different between products.
Unlike Z-drugs, BZD could be used for other indications
such as epilepsy or anxiety [56, 57]. However, we only
considered N5B1 IMS classification in this study, which is
for non-barbiturate drugs and is mostly used for insomnia,
while BZDs used for other indications are more likely to be
reported under other IMS classes, such as N5C (Antidepres-
sants and Anxiolytics).
We didn’t collect and analyze whole promotional materi-
als, but we relied on interviews of the company’s marketing
leader that provided a clear picture of the positioning and
promotion of PR-melatonin. The dichotomy of positioning
(or not) of PR-melatonin to help patients discontinue BZD/
Z-drugs was quite clear. Moreover, the people interviewed
were not aware of the ultimate research goal and therefore
were unlikely to be biased.
There were no prescriber interviews to appreciate the drivers
of their prescriptions, and the role of campaign and PR-melatonin
promotion. This could limit the interpretation of the reasons for
prescribing PR-melatonin as a means of discontinuing BZD/Z-
drug use. In this research we were not assessing the causal
relationship but just the existence or not of a relationship.
Finally, we didn’t perform a thorough review of cam-
paigns to appreciate the reasons for failure, as this wasn’t the
objective of our research.
Conclusion
Long-term prescription of BZD/Z-drugs is associated with
major adverse events including, but not limited to, falls and
fractures, domestic and traffic accidents, confusion, cogni-
tive impairment, Alzheimer's disease and cancer. The pro-
longed use of these drugs is thought to be related to severe
withdrawal symptoms and potential dependency. The chron-
ic and extensive use of BZD/Z-drugs has become a public
health issue and led to multiple campaigns to both reduce
the prescription of BZD/Z-drugs and achieve discontinua-
tion of long-term treatment. In our research, we observed the
failure of those campaigns when they were not associated
with the availability and uptake of sales of PR-melatonin.
The reimbursement of PR-melatonin may support a better
market penetration and a higher reduction of sales of BZD/
Z-drugs. The non-reimbursement of BZD/Z-drugs appeared
to have no effect on Z-drug prescription, and even showed
an increase in prescription during 2011. When considering
campaigns aiming to limit the usage of BZD/Z-drugs, policy
makers should carefully consider the availability of reim-
bursed effective and safe pharmacological alternatives.
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tive Commons Attribution License which permits any use, distribution,
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the source are credited.
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